AI Analyst Summary
IDEXX Laboratories holds a near-unassailable competitive position in veterinary diagnostics, with recurring instrument consumable revenues and a growing installed base driving 17.6% EPS growth and consistent analyst beats. The Bull case centers on durable pricing power, global pet healthcare tailwinds, and an expanding point-of-care diagnostics ecosystem that supports mid-teens earnings compounding. The key risk is valuation — at a PEG of 3.37 and 38.8x trailing earnings, any deceleration in growth or macro-driven softness in veterinary visit volumes could trigger a sharp de-rating.
Fundamentals
Pe
Trailing P/E: 38.8x | Forward P/E: 32.6x · 2.0/5
At 38.8x trailing and 32.6x forward, IDXX trades at a meaningful premium to the broader healthcare sector median. Valuation reflects the company's market leadership in veterinary diagnostics, but leaves limited margin of safety and prices in significant future execution.
Peg
PEG Ratio: 3.37 · 1.0/5
A PEG of 3.37 is well above the 3.0 threshold that signals expensive growth. Investors are paying a steep premium for each unit of earnings growth, which constrains near-term upside and increases sensitivity to any earnings disappointment.
Analyst Rating
Buy consensus (2.2) · 4.0/5
Consensus of 2.2 on an inverted scale maps to a Buy rating, supported by 8 Buy, 5 Hold, and 1 Sell across 13 analysts — a credible and sizable coverage universe. Broad bullish lean reflects confidence in IDXX's durable competitive moat in veterinary diagnostics.
Earnings Trend
EPS Growth YoY: +17.6% | Revenue Growth YoY: +9.7% · 3.0/5
17.6% YoY earnings growth is solid and above average, but falls short of the >25% threshold for a top score. Revenue growth of 9.7% is steady but modest for a premium-valued name. Growth is positive but not accelerating, warranting a neutral-to-constructive rating.
Price Target Beat
EPS Beat Rate: 4 of 4 quarters (recent history) · 3.0/5
IDXX has beaten EPS estimates in all 4 of the most recently reported quarters, a strong near-term signal. However, with only 4 quarters of data available, the full 8-quarter history is incomplete, capping the score at 3 per methodology. Trend is encouraging.
Management
Consistent execution; EPS beats across all recent quarters · 4.0/5
A perfect 4-of-4 recent EPS beat record and a broadly bullish analyst community signal disciplined execution and credible forward guidance. Capital allocation appears sound in a high-moat, recurring-revenue diagnostics business. Limited full-history data prevents a 5.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.